Compare Agilent Technologies Inc (A) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs Philip Morris International Inc. — how do they compare? Agilent Technologies Inc trades at $149.59 (market cap $42.00B), while Philip Morris International Inc. trades at $186.18 (market cap $289.90B). The key difference: Philip Morris International Inc. is far larger — about 6.9× Agilent Technologies Inc's market cap, and Philip Morris International Inc. pays the higher dividend (3.16%). Which is the better fit depends on your goals.
| A | PM | |
|---|---|---|
Market Cap | $42.00B | $289.90B |
Sector | Health | Consumer Staples |
52-Week High | $157.20 | $200.17 |
52-Week Low | $110.24 | $144.33 |
Enterprise Value | $43.55B | $333.02B |
Dividend Yield | 0.69% | 3.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
Philip Morris International (PM) trades at $189.57, up 0.81% today, with a bullish technical outlook and strong fundamentals. Recent earnings beats in Q1 and Q2 2026, alongside a 27.91% net margin in 2025, highlight profitability. However, the company faces headwinds from a $500 million impairment charge and reduced 2026 guidance due to cost pressures, as reported by Reuters on June 2, 2026.
The stock offers a dividend yield supported by cash flow, but risks include regulatory challenges and currency volatility. Analysts maintain a buy consensus with a $211.17 target, suggesting 11% upside, though investors should weigh near-term earnings pressure against long-term brand strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
